IL161248A0 - USE OF (11beta,17beta)-11-(1,3-BENZODIOXOL-5-YL) 17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER - Google Patents

USE OF (11beta,17beta)-11-(1,3-BENZODIOXOL-5-YL) 17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Info

Publication number
IL161248A0
IL161248A0 IL16124802A IL16124802A IL161248A0 IL 161248 A0 IL161248 A0 IL 161248A0 IL 16124802 A IL16124802 A IL 16124802A IL 16124802 A IL16124802 A IL 16124802A IL 161248 A0 IL161248 A0 IL 161248A0
Authority
IL
Israel
Prior art keywords
estra
benzodioxol
dien
propynyl
hydroxy
Prior art date
Application number
IL16124802A
Other languages
English (en)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of IL161248A0 publication Critical patent/IL161248A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16124802A 2001-10-26 2002-10-21 USE OF (11beta,17beta)-11-(1,3-BENZODIOXOL-5-YL) 17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IL161248A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204072 2001-10-26
PCT/EP2002/011732 WO2003037354A1 (en) 2001-10-26 2002-10-21 USE OF (11β, 17β)-11-(1,3-BENZODIOXOL-5-YL)-17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Publications (1)

Publication Number Publication Date
IL161248A0 true IL161248A0 (en) 2004-09-27

Family

ID=8181136

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16124802A IL161248A0 (en) 2001-10-26 2002-10-21 USE OF (11beta,17beta)-11-(1,3-BENZODIOXOL-5-YL) 17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
IL161248A IL161248A (en) 2001-10-26 2004-04-01 Use of (11,17)-11-(1, 3 - benzodioxol-5-yl)-17- hydroxy-17-(1-propynyl)-estra- 4, 9 - dien-3-one for the preparation of a medicament for the treatment of major depressive disorder

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161248A IL161248A (en) 2001-10-26 2004-04-01 Use of (11,17)-11-(1, 3 - benzodioxol-5-yl)-17- hydroxy-17-(1-propynyl)-estra- 4, 9 - dien-3-one for the preparation of a medicament for the treatment of major depressive disorder

Country Status (26)

Country Link
US (1) US20040266863A1 (https=)
EP (2) EP1652526B1 (https=)
JP (1) JP4647909B2 (https=)
KR (1) KR20050038580A (https=)
CN (1) CN100531738C (https=)
AT (2) ATE317700T1 (https=)
AU (1) AU2002348996B2 (https=)
BR (1) BR0213466A (https=)
CA (1) CA2463446C (https=)
CY (1) CY1110173T1 (https=)
DE (2) DE60230936D1 (https=)
DK (1) DK1652526T3 (https=)
EC (1) ECSP045080A (https=)
ES (1) ES2319563T3 (https=)
HR (1) HRP20040370B1 (https=)
HU (1) HUP0500070A3 (https=)
IL (2) IL161248A0 (https=)
IS (1) IS2702B (https=)
MX (1) MXPA04003781A (https=)
NO (1) NO332978B1 (https=)
NZ (1) NZ532429A (https=)
PL (1) PL206687B1 (https=)
PT (1) PT1652526E (https=)
RU (1) RU2302245C2 (https=)
WO (1) WO2003037354A1 (https=)
ZA (1) ZA200403088B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
BRPI0517847A (pt) * 2004-11-19 2008-10-21 Organon Nv combinação, usos de um inibidor de reabsorção de serotonina seletiva e de um antagonista do receptor de glicocorticóide, e, método para o tratamento de um indivìduo de uma espécie vertebrada sofrendo de depressão ou um distúrbio relacionado
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
WO2007131041A2 (en) * 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
WO2012106514A2 (en) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
WO2012145258A1 (en) * 2011-04-18 2012-10-26 Pop Test Cortisol Llc Hair loss treatment
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
DE4447401A1 (de) * 1994-12-23 1996-07-04 Schering Ag 14,17-C¶2¶-überbrückte Steroide
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
DE19727772A1 (de) * 1997-06-30 1999-01-28 Forschungszentrum Juelich Gmbh Magnetflußsensor mit ringförmiger Sonde
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
DE60232956D1 (de) * 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
WO2002096433A1 (en) * 2001-05-04 2002-12-05 Corcept Therapeutics, Inc. Methods for treating delirium using glucocorticoid receptor-specific antagonists
NZ531477A (en) * 2001-08-31 2006-10-27 Corcept Therapeutics Inc Use of a glucocorticoid receptor antagonist comprising a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton to decrease cognitive deterioration in adults with Down's syndrome

Also Published As

Publication number Publication date
ZA200403088B (en) 2005-01-24
HRP20040370A2 (en) 2004-08-31
IS7204A (is) 2004-03-31
EP1652526A3 (en) 2006-08-02
NO332978B1 (no) 2013-02-11
CA2463446A1 (en) 2003-05-08
PL206687B1 (pl) 2010-09-30
CN1582153A (zh) 2005-02-16
KR20050038580A (ko) 2005-04-27
AU2002348996B2 (en) 2008-06-05
HUP0500070A3 (en) 2012-09-28
RU2004116082A (ru) 2005-05-10
CN100531738C (zh) 2009-08-26
CA2463446C (en) 2010-02-23
JP2005521637A (ja) 2005-07-21
MXPA04003781A (es) 2004-07-30
WO2003037354A1 (en) 2003-05-08
IS2702B (is) 2010-11-15
EP1652526A2 (en) 2006-05-03
BR0213466A (pt) 2004-11-09
CY1110173T1 (el) 2015-01-14
ATE420649T1 (de) 2009-01-15
ATE317700T1 (de) 2006-03-15
HK1087357A1 (en) 2006-10-13
EP1441739A1 (en) 2004-08-04
IL161248A (en) 2010-12-30
DE60230936D1 (de) 2009-03-05
ECSP045080A (es) 2004-06-28
NO20041651L (no) 2004-04-23
RU2302245C2 (ru) 2007-07-10
HRP20040370B1 (hr) 2012-09-30
JP4647909B2 (ja) 2011-03-09
DE60209248D1 (de) 2006-04-20
US20040266863A1 (en) 2004-12-30
EP1441739B1 (en) 2006-02-15
EP1652526B1 (en) 2009-01-14
ES2319563T3 (es) 2009-05-08
PT1652526E (pt) 2009-02-06
DK1652526T3 (da) 2009-05-18
NZ532429A (en) 2004-10-29
PL369261A1 (en) 2005-04-18
HUP0500070A2 (hu) 2005-04-28

Similar Documents

Publication Publication Date Title
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
ES2124905T3 (es) Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.
MXPA04005784A (es) 2-fenilbenzofuranos sustituidos como agentes estrogenitos.
SG153645A1 (en) Hormone replacement therapy
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
IL159714A (en) Pharmaceutical composition for oral delivery comprising a fragment of parathyroid hormone and 5-cnac
HUP0402028A3 (en) Unsaturated 1-amino-alkylcyclohexane derivatives, pharmaceutical compositions containing them and use thereof
IL133632A (en) Use of a specific 5ht2 receptor antagonist for the preparation of pharmaceutical compositions useful in the treatment of the sleep apnea syndrome
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
EA200501739A1 (ru) Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
HUP0202347A2 (en) N-acylated pseudomycin analogs, process for their preparation, pharmaceutical compositions comprising thereof and their use
EP1361866A4 (en) EMULSIONS AS SOLID DOSAGE FORMS FOR ORAL ADMINISTRATION
HK1068097A (en) Use of (11beta, 17beta)-11- (1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4, 9-dien-3-one in the treatment of major depressive disorder
IL157272A0 (en) Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
NO20022712L (no) Umettede 14,15-syklopropanandrostaner, fremgangsmåte for deres fremstilling, og farmasöytiske preparater som inneholderdisse forbindelsene
EP1857110A3 (en) Hormone replacement therapy
BR0304292A (pt) Preparado de combinação de estrogênio-gestagênio e uso